Inflammatory Bowel Disease
Test in Focus
Mayo Clinic Laboratories’ IBDP2 serology panel detects for the presence of antibodies against Saccharomyces cerevisiae IgA and IgG, and anti-neutrophil cytoplasmic antibodies (pANCA) to confirm disease presence in patients for whom diagnosis is unclear. In this “Test in Focus” episode of the "Answers From the Lab" podcast, Melissa Snyder, Ph.D., explains how IBDP2, when used after first-line testing has failed, can distinguish between ulcerative colitis and Crohn’s disease.
“Ulcerative colitis and Crohn's disease are really clinical diagnoses where the physician takes into account the clinical picture, some imaging studies, and maybe pathology to make a diagnosis,” Dr. Snyder says. “And for most patients, this is enough. Inflammatory bowel disease serology testing can be useful in a small subset of patients to help when it's difficult to differentiate between ulcerative colitis and Crohn's disease.”
Inflammatory bowel disease serology testing at Mayo Clinic Laboratories incorporates measures that improve testing quality and ensure accuracy of test results, Dr. Snyder adds. “We want to make sure that when we provide a result to a patient, the patient can rely on that result, the physician can rely on that result.”
Listen to learn more about how IBDP2 can help distinguish between ulcerative colitis and Crohn’s disease for some patients with IBD.
Note: Podcasts will not play back on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Preferred: Serum gel
Acceptable: Red top
Specimen Volume: 1 mL
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.